Tyrosine kinase inhibitors (TKIs), such as sunitinib, serve as multitarget antiangiogenic agents and have exhibited great promise in the therapy of advanced/metastatic tumors by targeting vascular endothelial growth factor (VEGF) 5, 6. Here, VEGFA is linked to metastatic neoplasm.